FDA inspection
Cdymax (India) Pharma Private Limited: FDA inspection ending Apr 25, 2025
FDA inspection 1271325 · Official Action Indicated (OAI) · Bangalore
Key facts
| Inspection ID | 1271325 |
|---|---|
| Firm | Cdymax (India) Pharma Private Limited |
| FEI number | 3009882550 |
| Address | 77d & 116/117, Kiadb Industrial Area, Jigani |
| City | Bangalore |
| Country | India |
| Fiscal year | 2025 |
| Inspection end date | Apr 25, 2025 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 715022 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data